INTRODUCTION AND OBJECTIVES:
In the post-USPSTF era, the decision to identify and treat prostate cancer (PCa) remains controversial. The Decipher Prostate Cancer Classifier (DPCC) is a genomic test that independently predicts the risk of metastasis and prostate cancer specific mortality (PCSM). The studies used to validate the outcomes of the DPCC were comprised of mostly Caucasian men. Given the increased risk of PCSM in African American (AA) men, we sought to identify the utility of DPCC in an exclusively AA cohort and compare the results to previously well-established risk classification systems.
METHODS: Using an IRB-approved single institution database, we identified 72 AA men who had undergone radical prostatectomy between December 2008 and April 2016 for whom the DPCC was retrospectively ordered. Clinicopathologic variables were then used to risk stratify the patients based on the D'Amico and CAPRA-S risk classification systems. Comparisons were made to the DPCC risk scores based on low, intermediate, and high risk using a Chi-square analysis.
RESULTS: In this AA cohort, there was no association between DPCC risk scores and CAPRA-S scores (p ¼ 0.24). There was a relationship trend between DPCC risk scores and D'Amico risk categories, but this finding was not statistically significant (p ¼ 0.08). Among those with a low CAPRA-S and D'Amico risk, DPCC re-classified 28.6% and 12.5% of these men into a high risk category, respectively. Conversely, among men with combined intermediate and high CAPRA-S and D'Amico risk, 43.1% and 39.3% were re-classified as low risk based on DPCC, respectively. CONCLUSIONS: In this exclusive AA cohort, DPCC risk groups do not correlate with the CAPRA-S or D'Amico risk classification systems, which calls into question the clinical validity of these tools when counseling AA men. Prospective studies are needed to determine the true correlation of DPCC risk and cancer outcomes in this high risk subpopulation to better inform management decisions.
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MP20-05 A DIAGNOSTIC BIOPSY-BASED GENOMIC PROSTATE SCORE AS AN INDEPENDENT PREDICTOR OF PROSTATE CANCER DEATH AND METASTASIS IN MEN WITH LOCALIZED PROSTATE CANCER
INTRODUCTION AND OBJECTIVES: Prostate cancer (PCa) aggressiveness can be gauged by both short-and long-term outcomes including adverse surgical pathology, biochemical recurrence, development of metastases, and PCD. A 17-gene biopsy-based RT-PCR assay, which provides a Genomic Prostate Score (GPS) result (scale 0-100), is validated as an independent predictor of adverse pathology and biochemical recurrence after radical prostatectomy (RP). We sought to validate GPS further as a predictor of prostate cancer death (PCD) and metastasis in a large cohort of men with long term follow-up.
METHODS: A retrospective cohort study using a stratified sampling design was performed within Kaiser Permanente Northern California (KPNC). Of 6,184 men in the full cohort, all men with PCD and available tissue were included along with men sampled from the non-PCD men at a ratio of approximately 1:3. PCD was determined by review of Cancer Registry and KPNC mortality files; metastases were confirmed by review of imaging, biopsy or clinical data. Central review of diagnostic biopsies was performed by one uropathologist (JSH). RNA from archival diagnostic biopsies was assayed to generate GPS results. We assessed the association between GPS and metastasis and PCD as co-primary endpoints in pre-specified univariable and multivariable statistical analyses, based on Cox proportional hazards models accounting for sampling weights.
RESULTS: The final study population consisted of 279 men treated with RP for clinically low, intermediate and high-risk PCa between e240 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 
